{
  "id": 19660489,
  "title": "FDA Adds Rare Vision-Loss Warning to Ozempic and Other GLP-1 Drugs",
  "url": "https://urgent.news/2026/11/12/fda-adds-rare-vision-loss-warning-to-ozempic-and-other-glp-1-drugs",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-12T13:10:00.000Z",
  "source": {
    "name": "Colombia One",
    "slug": "colombia-one",
    "url": "https://colombiaone.com/2026/11/12/fda-vision-loss-warning-ozempic/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The U.S. Food and Drug Administration (FDA) is requiring manufacturers of popular diabetes and weight-loss medications, including Ozempic, Wegovy and Mounjaro, to add warnings about a rare eye condition that can cause sudden, permanent vision loss. The decision, announced on Nov. 9, 2026, follows an agency review that found a potential increased risk of nonarteritic […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}